These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 28079915

  • 21. Adjunctive therapies for Kawasaki disease.
    Campbell AJ, Burns JC.
    J Infect; 2016 Jul 05; 72 Suppl():S1-5. PubMed ID: 27241708
    [Abstract] [Full Text] [Related]

  • 22. Recent advances in the treatment of Kawasaki disease.
    Weng KP, Ou SF, Lin CC, Hsieh KS.
    J Chin Med Assoc; 2011 Nov 05; 74(11):481-4. PubMed ID: 22100015
    [Abstract] [Full Text] [Related]

  • 23. IVIG, aspirin, and Kawasaki disease.
    Morgan GJ, MacLeod C, Jenkins J, Stewart C, Craig B.
    J Pediatr; 2003 Aug 05; 143(2):280-1; author reply 281. PubMed ID: 12970651
    [No Abstract] [Full Text] [Related]

  • 24. State-of-the-art acute phase management of Kawasaki disease after 2017 scientific statement from the American Heart Association.
    Liu YC, Lin MT, Wang JK, Wu MH.
    Pediatr Neonatol; 2018 Dec 05; 59(6):543-552. PubMed ID: 29706362
    [Abstract] [Full Text] [Related]

  • 25. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
    Durongpisitkul K, Sangtawesin C, Khongphatthanayopthin A, Panamonta M, Sopontammarak S, Sittiwangkul R, Pongpanich B.
    Asian Pac J Allergy Immunol; 2006 Mar 05; 24(1):27-32. PubMed ID: 16913186
    [Abstract] [Full Text] [Related]

  • 26. Initial intravenous gammaglobulin treatment failure in Kawasaki disease.
    Wallace CA, French JW, Kahn SJ, Sherry DD.
    Pediatrics; 2000 Jun 05; 105(6):E78. PubMed ID: 10835091
    [Abstract] [Full Text] [Related]

  • 27. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 28. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
    Chen S, Dong Y, Yin Y, Krucoff MW.
    Heart; 2013 Jan 17; 99(2):76-82. PubMed ID: 22869678
    [Abstract] [Full Text] [Related]

  • 29. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
    Durongpisitkul K, Gururaj VJ, Park JM, Martin CF.
    Pediatrics; 1995 Dec 17; 96(6):1057-61. PubMed ID: 7491221
    [Abstract] [Full Text] [Related]

  • 30. [The role of immunosuppressive agents in Kawasaki disease: a discussion of two cases].
    Peyre M, Laroche C, Etchecopar C, Brosset P.
    Arch Pediatr; 2013 Jul 17; 20(7):748-53. PubMed ID: 23693156
    [Abstract] [Full Text] [Related]

  • 31. Kawasaki disease thirty years on.
    Curtis N, Levin M.
    Curr Opin Pediatr; 1998 Feb 17; 10(1):24-33. PubMed ID: 9529634
    [Abstract] [Full Text] [Related]

  • 32. A Masquerader of Disease: An Incomplete Presentation of Kawasaki Disease.
    Rezkalla J, Chang P, Peck E, Schimelpfenig M.
    S D Med; 2018 Feb 17; 71(2):54-57. PubMed ID: 29990410
    [Abstract] [Full Text] [Related]

  • 33. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
    Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E.
    Am J Ther; 2016 Feb 17; 23(6):e1293-e1299. PubMed ID: 25611359
    [Abstract] [Full Text] [Related]

  • 34. The immunologic effects of IVIG in Kawasaki disease.
    Leung DY.
    Int Rev Immunol; 1989 Feb 17; 5(2):197-202. PubMed ID: 8691053
    [Abstract] [Full Text] [Related]

  • 35. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
    Terai M, Shulman ST.
    J Pediatr; 1997 Dec 17; 131(6):888-93. PubMed ID: 9427895
    [Abstract] [Full Text] [Related]

  • 36. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 17; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 37. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications.
    De Rosa G, Pardeo M, Rigante D.
    Eur Rev Med Pharmacol Sci; 2007 Apr 17; 11(5):301-8. PubMed ID: 18074939
    [Abstract] [Full Text] [Related]

  • 38. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
    Saulsbury FT.
    Clin Pediatr (Phila); 2002 Oct 17; 41(8):597-601. PubMed ID: 12403377
    [Abstract] [Full Text] [Related]

  • 39. The Usefulness of Platelet-derived Microparticle as Biomarker of Antiplatelet Therapy in Kawasaki Disease.
    Kim HJ, Choi EH, Lim YJ, Kil HR.
    J Korean Med Sci; 2017 Jul 17; 32(7):1147-1153. PubMed ID: 28581272
    [Abstract] [Full Text] [Related]

  • 40. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome.
    Klassen TP, Rowe PC, Gafni A.
    J Pediatr; 1993 Apr 17; 122(4):538-42. PubMed ID: 8463897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.